LSVE 2018 boasts an impressive line up of speakers, each of whom brings valuable experience and guidance along with them. Join us on October 15, 2018 to learn from and work with our great speakers.
CHARLOTTE D'HULST, PhD
CEO and Co-Founder
Dr. D'Hulst was trained in bioengineering at the KULeuven (BE) and received her PhD in Biomedical Sciences from the University of Antwerp (BE). In 2009, she started working on the enigmatic sense of smell with Prof. Feinstein (CUNY), where she pioneered the MouSensor technology. In 2016,
she co-founded MouSensor, Inc. to digitize the sense of smell. As CEO, she has raised over $5M in early-stage funding and has secured a strategic partnership with IMEC (BE), a chip technology R&D hub.
MouSensor, Inc. engineers super sniffer mice to build a live nose-on-a-chip with the bold vision to detect, discover and digitize every single smell on this planet -ranging from the fragrances in a perfumer’s palette to the unique odors associated with diseases, such as Parkinson’s. The mission of the company is to ultimately establish the first-ever digital database of scent, much like the RGB code for vision.
Director, NY Metro Region
Maximizing Tax Incentives
Heather joined Danforth in 2015 with nearly 30 years of experience spanning private and public, start-up and later-stage organizations in the medical equipment and pharmaceutical industries. As an operational CFO, she has implemented strategic plans into corporate operations across functional areas including human resources, finance and accounting, research and development, manufacturing, quality, sales and marketing departments, while maintaining exceptional financial control and transparency to all stakeholders.
Her Danforth clients have included Homology Medicines, Immuneering, Kallyope, Opsonix, Pear Therapeutics and SpringWorks Therapeutics, among others. Prior to joining Danforth, she held finance leadership roles for Cytonome and AutoImmune. Heather earned a BA from the University of California, San Diego, and MBA from the University of Michigan Graduate School of Business.
Downstate Biotech Incubator
Jeffrey Hwang is the Entrepreneur-in-Residence at Downstate's Biotechnology Incubator and a consultant to startup teams. He was the President & COO of a privately held biotech after spending two decades in banking with JP Morgan covering energy and high tech companies. His degrees are from Harvard Business School, Wharton, and Horace Mann. Jeffrey is a born and raised New Yorker interested in helping local startup teams achieve the success their inventions or service can attain.
Director, Business Development
Paint-Points in the Back-Office
Erik Rocheford leads Stratacuity’s business development efforts for new and existing relationships. Having worked several years as an early discovery in-vivo pharmacologist as well as in a sales/science hybrid role at a preclinical CRO, Erik has a deeper scientific knowledge than many. He has earned a reputation for providing outstanding client service and his team is known for placing high-quality talent while paying attention to the smallest detail of every staffing assignment. His vast referral network and local market expertise have allowed him to become a trusted resource of Boston’s biopharmaceutical hub. Erik is passionate about new trends in the drug discovery community and enjoys contributing to team growth and overall workplace efficiency. Outside of work he is a happily addicted year-round surfer and enjoys spending time with his wife, two kids, and two dogs living it up here on the beautiful seacoast.
Case Study: Steering Committee Best Practices
Dr. Premsrirut is a founder and has served as President and CEO of Mirimus, Inc. since 2010. Mirimus specializes in developing platform technology for genetic manipulation of animal models of human disease and therapeutic modeling for drug discovery research, accelerating pipelines of bench to bedside discoveries using RNA interference and CRISPR/Cas gene editing technologies. Dr. Premsrirut was an MD/PhD Medical Scientist fellow at the SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory. Her research at CSHL in the lab of Dr. Scott Lowe specifically focused on determining the role of tumor suppressor genes in tumor maintenance of lung adenocarcinoma, in which she developed a speedy platform for the generation of cancer mouse models – research that laid the groundwork upon which Mirimus was founded. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. She was a Goldman Sachs 10,000 Small Businesses Scholar in Entrepreneurship and Babson College. Dr. Premsrirut is also currently an Assistant Research Professor of SUNY Downstate Medical School, serves as a Board Member of NY BIO, as well as a Board Member of BioBAT.
Partner and Co-Founder
Lunch Talk Moderator
Mark Simon, Torreya Partner and Co-Founder, heads the Biotech Advisory Team and participates in many of the firm’s biotech, pipeline, and specialty pharma transactions. He has expansive scientific and clinical knowledge across multiple therapeutic areas. In 30 plus years of advising biotech and specialty pharma companies, he has worked on more than 175 financing and M&A transactions totaling over $50 billion in value.
Before co-founding Torreya in 2007, Mark was a Managing Director and the Head of Life Sciences Investment Banking at Citigroup, where he covered global pharmaceutical companies, with a focus on large-capitalization players in the US, Europe, and Japan. Prior to his tenure at Citigroup, Mark served as a Managing Director at Robertson Stephens in San Francisco and New York. There, he was involved in raising 45% of all biotech dollars raised in the US from 1999-2001.
Before moving into investment banking, Mark was a Senior Biotech Research Analyst at Robertson Stephens, where he was named Wall Street All-Star Analyst three years in a row. Mark holds a B.A. in history from Columbia College and an M.B.A. from Harvard Business School.
He is Senior Advisor to the Milken Family Foundation’s Prostate Cancer Foundation and a Director of the Alliance for Aging Research.
Wilson Sonsini Goodrich & Rosati
Strategies for Protecting Your IP
Dr. Craig Kenesky is the head of the New York patents and innovation practice at the firm of Wilson, Sonsini, Goodrich & Rosati. Craig works with companies and investors in all life science sectors, with a focus on early stage, venture-backed companies. Craig’s practice focuses on taking life science companies from start up to exit, building a patent estate, and using IP to improve the outcomes of technology-driven business deals. Craig holds a PH.D. in organic chemistry from the University of Pennsylvania, and did a postdoctoral fellowship inbio-organic chemistry at Columbia. Craig teaches a class at Weill Cornell Medical School on how to launch and finance a life science company. The class covers the business and legal strategies and decisions involved in the founding and early-stage management of a fundable and successful biomedical start-up.
Senior Director, Worldwide Business Development
Open Mic: Ask Big Pharma
Bob Knowles has been leading cross-divisional business development teams at Pfizer for 20 years. He has focused on risk assessment of clinical stage treatments for Metabolic and GI diseases.
His transactions include Pfizer’s co-development collaborations with Merck on Steglatro/Steglujan (diabetes) and with Opko Health on somatrogen (growth hormone deficiency), Pfizer’s recent co-promotion with Exact Sciences for Cologuard (colon cancer screening), and Pfizer’s acquisitions of Anacor (dermatology) and Medivation (oncology). Bob’s early research career included a Ph.D. in virology, postdoctoral studies in immunogenetics, a faculty position at Sloan-Kettering, and he led the immunology research team at Johnson & Johnson.
GRANVILLE A. UNGERLEIDER
Ellington Healthcare Asset Management
Managing Member & President
Open Mic: Ask The VC
Granville A Ungerleider has over thirty years of investment banking and strategic advisory experience. He has initiated, led and implemented a broad array of initiatives with an emphasis on financial restructurings, mergers and acquisitions, divestitures, private equity investments and public offerings of debt and equity securities, including taxable and tax-exempt financings across a diverse set of industry sectors and geographic boundaries.
He develops financial structures to raise capital for growth-oriented companies, including media and telecommunication enterprises, alternative energy companies, healthcare/bio-pharma companies, and life insurance companies. He designs and structures municipal finance programs domestically and internationally, including the first private/municipal joint ventures for the construction of parking garages in Russia.
Mr. Ungerleider received a B.S. in Finance from New York University, an M.B.A. from Southern Illinois University and an MS in Accounting from Temple University. He holds FINRA series 24, 7, 53, 63, 79 and 99 licens
International Aids Vaccine Initiative
Senior Director of Process Development & Manufactring/Vaccine Development
RFP's and The Selection Process
Eddy Sayeed, Ph.D. is the Senior Director Process Development & Manufacturing/Vaccine Development, at the International AIDS Vaccine Initiative. He specializes in GMP manufacturing of vaccines and has more than 24 years of experience in the Vaccine Industry. He began his career at the Serum Institute of India Pvt. Ltd. and has extensive experience in Process & Assay Development and Large-scale manufacturing of licensed Measles, Mumps, Rubella and Rabies vaccines. Eddy also worked at CSL Ltd Melbourne (Australia) and was involved in undertaking validation activities for Influenza vaccine scale-up.
Eddy joined IAVI in 2002 as a Chemistry Manufacturing Controls (CMC) Lead and has worked on the development of over 49 HIV candidate vaccines based on plasmid DNA, bacterial delivery, several viral vectors, (MVA, AAV, Adenovirus, Sendai virus, CMV & VSV) and Protein based biological products (HIV ENV & Monoclonal antibodies). 26 of these candidates have advanced into early stage clinical studies. He has vast experience working with Contract Manufacturing Organizations (CMO) for undertaking Process/Assay development, cGMP manufacturing and QC testing of HIV vaccines for pre-clinical and clinical studies. Eddy also specializes in writing the CMC section for Regulatory and involved in interactions with Regulators during Pre-IND, IND and Scientific Advice Meetings with the US-FDA, MHRA and European Medicines Agency (EMA).
Open Mic: Ask the VC
Amanda works closely with the Venture Team managing venture and equity investments out of CI’s life science investment funds. An experienced life science–focused executive, Amanda spent more than 17 years in venture capital, corporate strategy, business development, company formation and early-stage operations.
Amanda was most recently at Baxalta/Shire, where she was a partner on the Ventures team, making equity investments out of a $200M strategic fund focused on areas of interest to Baxalta. Prior to Baxalta, Amanda was senior vice president at Scheer and Company, Inc., where she co-founded and helped manage a number of startup companies within the context of Scheer’s venture origination practice, in addition to providing high-level strategic business development and transaction advice to life science companies, entrepreneurs and investors.
Prior to Scheer, Amanda was the Bristol Myers Squibb Life Sciences Research Foundation postdoctoral scholar at Yale University, where her research focused on understanding molecular mechanisms contributing to cardiovascular disease.
Vendor Financing: What is it? How to get it?
Graham Anderson is the COO/CFO of Koios Medical, Inc., a company that uses its AI/Machine Learning technology for decision support for cancer detection and diagnosis. Koios’ first FDA cleared product is Koios DSä for Breast, software with vision that speeds accurate decision making and reporting of diagnostic ultrasound images.
Graham operates as a Managing Director of Kalon Partners LLC, a lower middle market private equity firm focused on consumer and healthcare businesses. Graham also serves as on the business advisory board of Aerolase Corp., a worldwide technology leader for laser skin health. Prior to becoming an independent sponsor at Kalon, Graham founded a secondary direct alternative investment fund that returned more than 2X invested capital with an 87% IRR. Graham also founded a cosmeceutical company that developed a dozen skin care for topical applications.
Graham served as a General Partner with EuclidSR Partners, a multi-stage venture capital and growth equity firm with $250 million under management. Graham’s software and healthcare investments produced a cash-on-cash return of 3.6X with a gross IRR of 15.7%.
Graham is a CFA Charterholder and a graduate of Yale College, the University of Glasgow and the Yale Law School.
Open Mic: Ask Big Pharma
John Gustofson is a Managing Director of AbbVie Ventures and invests across AbbVie’s therapy areas of Immunology, Oncology, and Neuroscience. He currently serves on the Board of Ribometrix and is a Board Observer for Disarm Therapeutics. Prior companies include Calimmune, Exicure and Kala Pharmaceuticals.
Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 20+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals, Therion Biologics, Boston Life Sciences and Ribozyme Pharmaceuticals. John also spent approximately 4 years in strategy consulting to the life sciences industry.
He holds a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University.
Director of Business Development
Sticker Shock: Bridging the Gap
Debra Inger is Director of Business Development for BioSurplus, a leading reseller of preowned laboratory instrumentation. Debra is also co-founder and co-owner of NTS Laboratory Equipment and was previously the Business Manager of centrifugal evaporator manufacturer, Genevac. Prior to her career in the laboratory instrumentation industry, she spent 14 years in the HVAC industry in both the Orlando and NYC markets. Having earned an Accounting degree and MBA from The University of Central Florida, Debra brings a well rounded business perspective to any business opportunity.
Randy D. Milby, MBA
Mr. Randy D. Milby, MBA, CEO of Hillstream Bio. He served as the Chief Executive Officer of CorMedix, Inc. from July 2015 to October 2, 2016 and as its Chief Scientific Officer until October 2, 2016. Mr. Milby served as the Chief Executive Officer of CorMedix, Inc. from January 1, 2013 to July 2015 and served as its Chief Operating Officer from May 2, 2012 to January 1, 2013.
Mr. Milby Co-founded MW Bridges, LLC in 2010 and has been its Managing Director since 2010 and Managing Partner. Mr. Milby has been the President and Secretary of Hillstream Pharma Inc. since January 31, 2006 and also serves as its Principal Executive Officer and Principal Financial Officer. He serves as Pharmaceutical Consultant at Mattson Jack Group. Mr. Milby served as the Global Business Director for Dupont since January 2004; and its Global Marketing Director from June 1999 to January 2004. He also served as a Healthcare Analyst at Goldman Sachs & Co. Mr. Milby also served as President and Secretary of Verbena Pharmaceuticals Inc. from January 31, 2006 to December 2007 and served as its Principal Executive Officer and Principal Financial Officer until December 2007. He served as Director of CorMedix, Inc. from August 2013 to October 2, 2016. He served as Director at Verbena Pharmaceuticals Inc. from January 31, 2006 to December 2007. He has done Sales and Marketing Management Development Program at Bristol-Myers Squibb. He served as Senior Director DuPont Merck Pharmaceuticals and responsible for global new product planning and acquisition; global product manager during launch of COZAAR® (losartan) with multi-billion dollar sales. Mr. Milby received a Bachelor of Science in Pharmacy from the University of Kansas in 1979 and a Masters in Business Administration from Washington University in St. Louis in 1985.
Clean Your Room: Ready Made SOPs
Denise Aronson is a pioneer in the life science health and safety industry. Denise founded Safety Partners Inc. in 1992. Since then, Denise and her team have implemented safety programs for more than 400 top life science companies. Prior to founding Safety Partners, Denise served as an environmental, health, and safety manager at T Cell Sciences, and managed a clinical prenatal diagnostics laboratory. She began her career as a research associate at Beth Israel Deaconess Hospital in Boston, after receiving a BS in Biochemistry from the University of New Hampshire. Denise is a certified chemical hygiene officer through the National Registry of Certified Chemists. She is active in more than 20 professional societies and trade organizations, and was a founding member of the New Hampshire Bio/Medical Council, Preferred Provider Leads Group; the Tom Vance, Life Sciences Connector Group; and the Cambridge Chamber of Commerce, Life Sciences Leads Group. She is a regular on the industry speaking circuit, a member of the MassBio SEF Working Group, and an American Chemical Society (ACS) Expert. Denise also serves on the Advisory Board for the UMass Lowell Department of Work Environment as well as the Boards of The Bioscience Network and The Waldorf High School of Massachusetts Bay. Safety Partners is a Certified Woman-Owned Business, and has been named one of the 25 Best Small Companies by Working Mother magazine.
Senior US Partner
Josh Stephens serves as Chief of Staff for the Strategic Investments Group at the New York City Economic Development Corporation (NYCEDC). His portfolio includes oversight of team operations and strategy, unlocking life sciences real estate, business attraction/retention and working with the private sector to establish a network spaces to serve life sciences startups. Prior to this role, Josh served as Chief of Staff for Initiatives and Senior Project Manager for LifeSci NYC at NYCEDC. Before moving to New York in 2016, Josh spent five years working for Oconee County, South Carolina, to craft community-orientated solutions and service models focused on advancing the goals of communities. He worked with county leadership on budgeting and policy development while serving as Assistant to the County Administrator, as well as building citizen-centered service delivery solutions while serving as Deputy Director of Community Development. Josh is a graduate of Clemson University.
Maximizing Tax Incentives
Strategic Investments Group at NYCEDC
Chief of Staff
Business Performance Advisor
Kim Fields is a business professional who consults small and medium-sized business owners and executives on ways to improve operational efficiencies and impact profitability. As a former business owner, Kim is tuned into the concerns that keep owners awake at night and puts them at ease with her expertise, attention to detail and genuine interest in their business needs. Her personal slogan is “Connecting the Dots” because she is a savvy networker who consistently puts the right professionals together to further their business growth.
Certified Business Performance Advisor
Pain-Points in the Back-Office
Dorothy is a Certified Business Performance Advisor with Insperity since 2007. She has served hundreds of early stage and emerging growth companies with human resource solutions that encompass fortune 500 employee benefits, award winning HRIS software, human Capital management and compliance and expertise.
Dorothy hold a BA in Economics and History from MaryMount College and serves on the Advisory Board of New Ground a Non Profit on Long Island that works with families and veterans providing housing and educational assistance.
Director Cell Technology
RFP's and the Selection Process
Alfred Luitjens is the Director Cell Technology at Batavia Biosciences. He has a profound background in development and production of vaccines, with more than 30 years of experience. He worked for research & development at Solvay, DSM Biologics and Crucell. He had a management position at the Animal Science Group and was senior manager process architecture at GSK. At Batavia Biosciences Alfred is involved in the BMGF and CEPI global health projects.
Center for Medicine in the Public Interest
Peter Pitts is President of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Peter was FDA’s Associate Commissioner for External Relations, serving as senior communications and policy adviser to the Commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug task force and as a Special Government Employee (SGE) consultant to the FDA’s RiskCommunications Advisory Committee.Specific areas of global policy expertise include FDA policy and process, health care technology assessment and reimbursement issues, real world evidence, social media, off label-communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.
In 2010, he was named by Modern Healthcare magazine as one of the 300 “most powerful people in American healthcare.”
support group. Prior to that he was the Principal Consultant in his own regulatory consulting firm for over three years. He also worked for four years in a startup biopharm company (joining as employee number 12) which went IPO but which no longer exists.
He also spent 15 years in increasingly responsible Regulatory Affairs roles at Bayer, where he led teams which secured four NDA approvals in that period. Among other things, he was the Regulatory Lead for the approval of Cipro in Anthrax. When he left Bayer in 2005 he was Global Therapeutic Area Head (Anti-Infectives) Regulatory Affairs.
He has served as lead regulatory spokesperson for hundreds face-to-face and teleconference meetings with the FDA, including leading company presentations to FDA Advisory Committees; he also had the honor of being the first industry representative ever invited to speak at the Project Manager Staff Forum at FDA.
He received my MBA from Fairleigh Dickinson University and his Bachelors Degree in Chemical Engineering from Clarkson University, and is RAC, Regulatory Affairs Certified.
Andrew S. Verderame joined Pharmalex in 2014 and serves as Senior US Partner, Regulatory Affairs and Development Services. PharmaLex is a 750 consultants strong, global consulting company providing regulatory, pharmacovigilance, quality/compliance, statistics, medical device, risk management and epidemiology, and pharmaceutical development services to pharma and biotech companies of all sizes. The US group has grown considerably in recent years, both organically and through mergers with other consulting organizations, and now totals 140 employees. Andy has over 30 years invested in the pharma industry and regulatory affairs, and most recently before joining PharmaLex he was in the position of Therapeutic Area Head, Global Regulatory Affairs for EMD Serono in the US – responsible for the Fertility and Endocrinology Therapeutic Areas, and the US Head Regulatory for the marketed product portfolio, CMC, and the Development
FOUNDER & CEO
Sticker Shock: Bridging the Gap Between Academic and Commercial Pricing
Peter Leonardi, Ph.D., M.B.A. – Founder and CEO of OmniCyte, a biotech company developing a next generation Immuno-Oncology therapeutic utilizing the company’s proprietary platform technology to harness the patient’s own immune system to targeted a specific tumor type. Prior to founding OmniCyte, Dr. Leonardi was the Chief of Finance and Administration at Protein Sciences Corporation, a private biotech company which received FDA approval for the first recombinant seasonal influenza vaccine. In 2017, the company was sold to Sanofi for $750M. Previously, Peter was a Director at Five Prime Advisors, a New York City based boutique healthcare investment bank. Prior to that, Peter was VP of Channel Development at ProCure Treatment Centers (a VC backed cancer treatment company). Peter earned his MBA, with a concentration in Finance, at Carnegie Mellon’s Tepper School of Business. Peter earned his Ph.D. in Molecular Biology at NYU School of Medicine, where he was a National Cancer Institute Fellow. Peter also attended the US Air Force Academy and the University of Connecticut.
Product Development to Project Management
Tunnell Life Sciences
Kip brings to Tunnell Life Sciences Consulting more than 25 years of experience as a management consultant, during which time he has also temporarily held various highly visible leadership positions at some of the world’s top life sciences companies. Kip has temporarily worked inside the life sciences industry on two occasions, both during periods of significant transformational change: first inside Wyeth, pre-Pfizer merger; and, again inside Merck, post-Schering merger. In both cases he led business process management (BPM) groups: at Wyeth, in the manufacturing division; and, at Merck, in the research and development division. In January 2015 Kip joined Tunnell where he brings his product development program management experience to bear to improve the probability of successful regulatory filing and product launch. He also leads the data integrity practice at Tunnell and consults, teaches, speaks and publishes regularly on topics of data integrity and quality systems.
His technical experience includes the fields of quality assurance and regulatory affairs, GMP and IT compliance, technical operations and product supply. His areas of leadership expertise include business transformation, new business development, organizational change leadership and program / project management. Kip holds and maintains various credentials, including the Project Management Professional (PMP) credential and the Program Management Professional (PgMP) credential. He has also completed graduate studies in Drug Development at Temple University, and holds multiple business degrees from Eastern University: an MBA in Management and an undergraduate degree in Management of Information Systems.
Misti Ushio is the CEO of TARA Biosystems.
TARA Biosystems develops physiologically relevant 3D tissue models for drug discovery and development applications. The company’s Biowire™ II platform enables generation of large amounts of human relevant data for predictive drug development. TARA accelerates discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities, and also evaluates early cardiac risk assessment of drug discovery candidates.
Dr. Ushio has over 20 years of experience in the biotechnology and pharmaceutical industry, and early stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she advised and invested in life science companies to help them translate their transformational science into commercially successful companies.
Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also serves as a Director on the Boards of private and public life science companies.
Robert, 21, is Founder & CEO of OneH - an online platform connecting startups with a global pool of investors & partners based on their shared financial & strategic interests. He began his career at 16 where he worked as Director of Digital Marketing for Research Frontiers, Inc. By 17, he was promoted by the Board of Directors to serve as Director of Market Development - the youngest person in the company's history to hold such position. Here, he was responsible for coupling the company's marketing strategy with their business development strategy and product pipeline. He was directly responsible for developing two advertisements featured in Times Square and played an integral role in bringing the company's technology out to the USA Pavilion at the Milan World's Fair (Expo Milano 2015).
At 18, Robert left Research Frontiers to found GlassHorse Ventures, where he built and managed an investor network of 45+ investors. Robert sits on their Board of Advisors of Zuli alongside Guy Kawasaki and Leonardo DiCaprio. Today, Robert runs OneH where he works with hundreds of startups, investors, enterprises, accelerator programs, and more to help them work together & develop their respective businesses. 100+ companies, 150+ investors, & 15,000 users later, OneH is a startup’s go to platform to launch their company and showcase themselves to the public. Because of his experience, Robert has an in depth understanding of the startup business development process from the perspective of both the issuer & the investor.
Pain-Points in the Back-Office
Founder & CEO
Client & Scientific Portfolio Manager
Case Study: Steering Committee Best Practices
Chris oversees a team of project managers and provides scientific support for Research Models and Services (RMS) at Charles River. He also leads the CRISPR based Model Creation service in North America. Chris is a molecular biologist with experience ranging from generating and characterizing animal models, to large scale genotyping and sequencing. Before joining Charles River in 2016, he worked for Beckman Coulter, focusing on nucleic acid extraction, sequencing and automation. He earned BS degrees in Biology and Literature from Worcester Polytechnic Institute in 2006 and received his PhD in Biomedical Science from the University of Massachusetts Medical School in 2012.
An accomplished entrepreneur, Yash has over 20 years of experience with establishing and growing technology-based companies in the life sciences. He is formally trained as an optical engineer with an emphasis in imaging technologies. Yash co-founded his first company, Optical Insights, in 1997. He led the optical design and software development efforts as well as managing financial operations from early stage inception to its successful exit to Roper Industries in 2005.
In 2010, Yash joined the technical co-founders of Xeris Pharmaceuticals to formally launch the company in 2011. From 2011 to 2014, Yash served as COO and/ or CFO at Xeris building the operational infrastructure and leading fundraising efforts. Over this period, Xeris raised over $60M in private capital and $15M in non-dilutive funding. Having successfully grown Xeris to a point of financial and operational stability, Yash left in September 2016 to focus on new projects. Xeris is now a public company listed on the Nasdaq.
Yash is currently co-founder and CEO of CherryCircle Software, Inc. which develops cloud-based knowledge management solutions for lifecycle product management in pharmaceuticals and medical devices. He is also CEO of NanoMedical Systems, which he joined in the beginning of 2017 to move the company beyond proof-of-concept to development and commercialization of drug delivery and diagnostics products based on their proprietary nanofluidics technologies.
Product Development to Project Management
Kathleen Coviello is the Vice President of Technology & Life Science Investments at the New Jersey Economic Development Authority (EDA). She is responsible for working closely with the emerging technology and life science companies and investors in the state and delivering the various Edison Innovation Fund products to this community. She joined the Authority in August 2005 as a program manager.
Under Ms. Coviello’s direction, along with her team, the EDA has delivered over $1 Billion in direct investments, business incentives, tax credits, and venture fund investments through the Edison Innovation Fund. Coviello’s related accomplishments include crafting, for the first time at the EDA, financing instruments with warrants to support the NJ technology community and the EDA’s conversion in several portfolio companies to be a preferred stock holder. She has also assembled and runs several technology advisory boards comprised of private sector industry specialists, which supports the EDA’s commitment to a public private partnership.
Maximizing Tax Incentives
NJ Economic Development Authority (EDA)
VP of Tech and Life Science Investments
Subscribe to Updates from LSVE Conference